Breaking into new grounds: Orthocell eyes $75M Canadian market with game-changing nerve repair product

In a bold move to capture a significant share of the global nerve repair market, Orthocell, a pioneer in regenerative medicine, has submitted a regulatory application to Health Canada for its leading product, Remplir. This step marks a strategic expansion into the Canadian market, valued at approximately US$75 million, with approvals anticipated in the latter…

Orthocell spikes on research result

Nerve technology developer Orthocell (ASX:OCC) has reported a study validating ‘high quality nerve repair’ from its CelGro treatment. The pre-clinical study indicated CelGro facilitated the regeneration of severed peripheral nerves, returning them to normal nerve structure. This reinforces earlier human trials that CelGro restored nerve sensation, reducing the need for sutures. Orthocell managing director, Paul…

Manufacturing news briefs – stories you might have missed

ARE receives $5m grant for rare earths development Australian Rare Earths has received a $5 million grant from the federal government’s International Partnerships in Critical Minerals Program. The funding will support additional metallurgical test work, completion of a pre-feasibility study and building/operating a demonstration plant at the company’s Koppamurra project, a frontier ionic clay rare…